<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 14, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05344508</url>
  </required_header>
  <id_info>
    <org_study_id>INS1007-EAP</org_study_id>
    <nct_id>NCT05344508</nct_id>
  </id_info>
  <brief_title>An Expanded Access Study to Assess Brensocatib for Participants With Non-Cystic Fibrosis Bronchiectasis</brief_title>
  <official_title>Brensocatib in Patients With Non-Cystic Fibrosis Bronchiectasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Insmed Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Insmed Incorporated</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to allow early access to brensocatib for participants with&#xD;
      non-cystic fibrosis bronchiectasis (NCFBE) who have successfully completed the INS1007301&#xD;
      ASPEN Clinical trial.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants will receive brensocatib 10 mg, oral tablets, once daily.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Available</overall_status>
  <study_type>Expanded Access</study_type>
  <has_expanded_access>No</has_expanded_access>
  <expanded_access_info>
    <expanded_access_type_treatment>Yes</expanded_access_type_treatment>
  </expanded_access_info>
  <condition>Non-Cystic Fibrosis Bronchiectasis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Brensocatib</intervention_name>
    <description>Brensocatib tablets</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participant had agreed to provide their informed consent to participate per local&#xD;
             requirements.&#xD;
&#xD;
          -  Participant had successfully completed Clinical Trial INS 1007-301 ASPEN, including&#xD;
             the End of study Visit 12 prior to receiving treatment.&#xD;
&#xD;
          -  Requests for Post-Trial access for brensocatib had come from ASPEN investigator.&#xD;
&#xD;
          -  Had received brensocatib treatment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participant had experienced a serious adverse event deemed to be related to&#xD;
             brensocatib during the study and required permanent participant is continuation.&#xD;
&#xD;
          -  The participant is immunocompromised or chronically treated with any investigational&#xD;
             or commercialized immunomodulatory agent that is directed to any component of the&#xD;
             adaptive or innate immune systems.&#xD;
&#xD;
        Note: The use of any immunomodulatory agents (including but not limited to: bortezomib,&#xD;
        ixazomib, thalidomide, cyclophosphamide, mycophenolate, Janus kinase inhibitors, IFN-Î³, and&#xD;
        azathioprine) is prohibited during the program.&#xD;
&#xD;
          -  The participant had undergone continuous use of high dose non-steroidal&#xD;
             anti-inflammatory drugs.&#xD;
&#xD;
          -  The participant had undergone chronic use of systemic steroids for any chronic&#xD;
             condition, except steroids with topical anti-inflammatory activities (ie, oral&#xD;
             budesonide).&#xD;
&#xD;
          -  Participant had planned to receive live attenuated vaccines during the program&#xD;
             (treatment must be postponed until 4 weeks after the last dose of drug).&#xD;
&#xD;
          -  Participant had planned to use investigational drugs.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Insmed Medical Information</last_name>
    <phone>1-844-446-7633</phone>
    <email>medicalinformation@insmed.com</email>
  </overall_contact>
  <verification_date>April 2022</verification_date>
  <study_first_submitted>April 6, 2022</study_first_submitted>
  <study_first_submitted_qc>April 18, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">April 25, 2022</study_first_posted>
  <last_update_submitted>April 18, 2022</last_update_submitted>
  <last_update_submitted_qc>April 18, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">April 25, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cathepsin G</keyword>
  <keyword>CKD-EPI</keyword>
  <keyword>NCFBE</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bronchiectasis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

